(TRIN-2755)-药物靶点：DNA_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TRIN2755、TRIN 2755

靶点

DNA(DNA)

作用机制

DNA抑制剂(DNA抑制剂)

治疗领域

肿瘤

在研适应症-

非在研适应症

肉瘤、实体瘤

原研机构

Trin Therapeutics GmbH

在研机构-

非在研机构

Trin Therapeutics GmbH

最高研发状态(全球)无进展临床1期

首次获批日期(全球)-

最高研发状态(中国)-

特殊审评-

结构

分子式C20H22N4O5

InChIKeyVJRVZEJVUUHRRS-UHFFFAOYSA-N

CAS号1421747-32-1

关联

1

项与 TRIN-2755 相关的临床试验

NCT01259518 / Unknown status临床1期

A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens

This is an open-label, parallel-group, two-center, safety, activity and pharmacokinetic study of TriN 2755 given at increasing dose levels as intravenous infusions administered over 4 hours. The study is divided into two parts: Part I a dose escalation phase and Part II an extension phase.

开始日期2009-11-01

申办/合作机构

Trin Therapeutics GmbH

[+2]

100 项与 TRIN-2755 相关的专利（医药）

登录后查看更多信息

1

项与 TRIN-2755 相关的文献（医药）

2017-03-01·Veterinary and comparative oncology2区 · 农林科学

Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study^†.

2区 · 农林科学

Article

作者: I Athanasiadi ; C Geigy ; R A Hilger ; V Meier ; C Rohrer Bley

TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use, carrying the triazene group as the cytotoxic principal. Using a standard 3 + 3 design, a phase I study was performed in tumour bearing dogs to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755. Thirty dogs were included in the study. TriN 2755 was administered over 20 min on two consecutive weeks per month for a total of three cycles. The starting dose was 25 mg kg^-1 and the MTD was 74.6 mg kg^-1 . Three dogs experienced DLT, which was characterized by gastrointestinal adverse events. The PKs of TriN 2755 and its main metabolites in plasma and sputum are described in a two-compartment model. The response rate for 19 of 30 dogs was 47.3% (six partial remission, three stable disease) and the median progression-free interval (PFI) for the responders was 47 days (range: 21-450 days).